

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

ABBVIE INC., ABBVIE LTD., and )  
NEUROCRINE BIOSCIENCES, INC. )  
Plaintiffs, )  
v. )  
ALKEM LABORATORIES LIMITED, et al., ) C.A. No. 22-1423-RGA-JLH

Defendants. )

---

ABBVIE INC., )  
Plaintiff, )  
v. ) C.A. No. 23-374-RGA  
TEVA PHARMACEUTICALS, INC., )  
Defendant. )

---

ABBVIE INC., )  
Plaintiff, )  
v. ) C.A. No. 23-448-RGA  
HETERO LABS LIMITED, HETERO LABS )  
LIMITED UNIT-V, and HETERO USA INC., )  
Defendants. )

PRINSTON PHARMACEUTICAL INC., )  
ZHEJIANG HUAHAI PHARMACEUTICAL )  
CO., LTD., and SOLCO HEALTHCARE US, )  
LLC, )  
Defendants. )  
)

PRINSTON PHARMACEUTICAL INC., )  
ZHEJIANG HUAHAI PHARMACEUTICAL )  
CO., LTD., and SOLCO HEALTHCARE US, )  
LLC, )  
Defendants. )  
)

ABBVIE INC., )  
Plaintiff, )  
v. ) C.A. No. 23-684-RGA

SUN PHARMACEUTICAL INDUSTRIES )  
LIMITED, )  
Defendant. )  
 )

ABBVIE INC., )  
Plaintiff, )  
v. )  
LUPIN LIMITED and LUPIN ) C.A. No. 23-750-RGA  
PHARMACEUTICALS, INC., )  
Defendants. )

**STIPULATION AND [PROPOSED] ORDER CONCERNING  
AMENDED COMPLAINT AND CONSOLIDATION**

WHEREAS, on October 27, 2022, Plaintiffs AbbVie Inc., AbbVie Ltd, and Neurocrine Biosciences, Inc. (collectively, “Plaintiffs”) filed C.A. No. 22-1423-RGA-JLH in this Court in connection with Abbreviated New Drug Applications in which the defendants in those cases seek approval to market a generic version of Plaintiffs’ ORILISSA® product in the United States prior to the expiration of U.S. Patent Nos. 7,056,927, 7,716,211, 7,419,983, 10,537,572, 10,682,351, and/or 11,344,551;

WHEREAS, in April, June, and July 2023, Plaintiff AbbVie Inc. filed the following six Hatch-Waxman actions in this Court in connection with Abbreviated New Drug Applications in which the defendants in those cases seek approval to market a generic version of Plaintiffs' ORILISSA® product in the United States prior to the expiration of U.S. Patent Nos. 10,537,572, 10,682,351, and/or 11,542,239: C.A. Nos. 23-374-RGA, 23-448-RGA, 23-470-RGA, 23-607-RGA, 23-684-RGA, 23-750-RGA;

WHEREAS, pursuant to Fed. R. Civ. P. 15(a)(2) and D. Del. LR 15.1, the parties agree that Plaintiffs may file the Amended Complaint attached hereto as Exhibit 1;

WHEREAS, C.A. Nos. 22-1423-RGA-JLH, 23-374-RGA, 23-448-RGA, 23-470-RGA, 23-607-RGA, 23-684-RGA, 23-750-RGA are related cases involving common questions of law and fact, and the parties agree that interests of efficiency for the parties and the Court will be best served if they are consolidated;

WHEREAS, Plaintiffs and Defendants Alkem Laboratories Limited, Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Pvt. Ltd., MSN Pharmaceuticals Inc., Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Solco Healthcare US, LLC, Sandoz Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceuticals, Inc., Zenara Pharma Private Limited and Biophore India Pharmaceuticals Private Ltd. (collectively, "Defendants") agree to adopt and be bound by the same protective order that has been entered in C.A. No. 22-1423-RGA-JLH (D.I. 101) in C.A. Nos. 23-374-RGA, 23-448-RGA, 23-470-RGA, 23-607-RGA, 23-684-RGA, 23-750-RGA;

WHEREAS, Plaintiffs and Defendants agree to negotiate in good faith a revised schedule that preserves the existing trial date in C.A. No. 22-1423-RGA-JLH; now therefore,

IT IS HEREBY STIPULATED AND AGREED TO, by and between the parties, subject to the approval of the Court, as follows:

1. Pursuant to Fed. R. Civ. P. 15(a)(2) and D. Del. LR 15.1, Plaintiffs may file the Amended Complaint attached hereto as Exhibit 1. A version of the Amended Complaint indicating in what respects it differs from the Original Complaint is attached hereto as Exhibit 2.

2. The Amended Complaint shall be filed as a separate docket entry item upon entry of this stipulation and shall be deemed served upon filing.

3. The following cases shall be consolidated for all purposes: C.A. Nos. 22-1423-RGA-JLH, 23-374-RGA, 23-448-RGA, 23-470-RGA, 23-607-RGA, 23-684-RGA, 23-750-RGA. Hereafter, all papers in the consolidated case shall be filed in C.A. No. 22-1423-RGA-JLH and shall bear the following caption (the “Consolidated Action”):

ABBVIE INC., ABBVIE LTD, and )  
NEUROCRINE BIOSCIENCES, INC. )  
 )  
 Plaintiffs, )  
 )  
 v. ) C.A. No. 22-1423-RGA-JLH  
 ) CONSOLIDATED  
ALKEM LABORATORIES LIMITED, et al., )  
 )  
 Defendants. )  
 )  
 )

---

4. The parties in the Consolidated Action shall be bound by the Protective Order that is in effect in C.A. No. 22-1423-RGA-JLH (D.I. 101).

/s/ Jeremy A. Tigan  
Jack B. Blumenfeld (No. 1014)  
Jeremy A. Tigan (No. 5239)  
Megan E. Dellinger (No. 5739)  
MORRIS, NICHOLS, ARSHT & TUNNELL LLP  
1201 North Market Street  
P.O. Box 1347  
Wilmington, DE 19899  
(302) 658-9200  
jblumenfeld@morrisnichols.com  
jtigan@morrisnichols.com  
mdellinger@morrisnichols.com

*Attorneys for Plaintiffs AbbVie Inc., AbbVie  
Ltd, and Neurocrine Biosciences, Inc.*

/s/ Daniel A. Taylor  
Neal C. Belgam (No. 2721)  
Daniel A. Taylor (No. 6934)  
SMITH, KATZENSTEIN & JENKINS LLP  
1000 West Street, Suite 1501  
Wilmington, DE 19801  
(302) 652-8400  
nbelgam@skjlaw.com  
dtaylor@skjlaw.com

*Attorneys for Defendant Alkem Laboratories  
Ltd.*

/s/ Geoffrey G. Grivner

Geoffrey G. Grivner, Esq. (No. 4711)  
Kody M. Sparks, Esq. (No. 6464)  
BUCHANAN INGERSOLL & ROONEY PC  
500 Delaware Avenue, Ste. 720  
Wilmington, DE 19801  
(302) 552-4200  
geoffrey.grivner@bipc.com  
kody.sparks@bipc.com

*Attorneys for Defendants Hetero Labs Limited, Hetero Labs Limited Unit-V, and Hetero USA Inc.*

/s/ Anne Shea Gaza

Anne Shea Gaza (No. 4093)  
Samantha G. Wilson (No. 5816)  
YOUNG CONAWAY STARGATT & TAYLOR, LLP  
Rodney Square  
1000 North King Street  
Wilmington, DE 19801  
(302) 571-6600  
agaza@ycst.com  
swilson@ycst.com

*Attorneys for Defendants MSN Laboratories Private Ltd., MSN Life Sciences Pvt. Ltd., and MSN Pharmaceuticals Inc.*

/s/ Dominick T. Gattuso

Dominick T. Gattuso (No. 3630)  
HEYMAN ENERIO GATTUSO & HIRZEL LLP  
300 Delaware Avenue, Suite 200  
Wilmington, DE 19801  
(302) 472-7311  
dgattuso@hegh.law

*Attorney for Defendant Sandoz Inc.*

/s/ James M. Lennon

James M. Lennon (No. 4570)  
DEVLIN LAW FIRM LLC  
1526 Gilpin Avenue  
Wilmington, DE 19806  
(302) 449-9010  
jlennon@devlinlawfirm.com

*Attorney for Defendants Lupin Limited and Lupin Pharmaceuticals, Inc.*

/s/ Daniel A. Taylor

Neal C. Belgam (No. 2721)  
Daniel A. Taylor (No. 6934)  
SMITH, KATZENSTEIN & JENKINS LLP  
1000 West Street, Suite 1501  
Wilmington, DE 19801  
(302) 652-8400  
nbelgam@skjlaw.com  
dtaylor@skjlaw.com

*Attorneys for Defendants Princeton Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., and Solco Healthcare US, LLC*

/s/ Anne Shea Gaza

Anne Shea Gaza (No. 4093)  
Samantha G. Wilson (No. 5816)  
YOUNG CONAWAY STARGATT & TAYLOR, LLP  
Rodney Square  
1000 North King Street  
Wilmington, DE 19801  
(302) 571-6600  
agaza@ycst.com  
swilson@ycst.com

*Attorneys for Defendants Sun Pharmaceutical Industries Limited*

/s/ Karen E. Keller

Karen E. Keller (#4489)  
Nathan R. Hoeschen (#6232)  
Emily S. DiBenedetto (#6779)  
I.M. Pei Building  
1105 North Market Street, 12th Floor  
Wilmington, DE 19801  
kkeller@shawkeller.com  
nhoeschen@shawkeller.com  
edibenedetto@shawkeller.com

*Attorney for Defendant Teva Pharmaceuticals,  
Inc.*

/s/ Daniel A. Taylor

Neal C. Belgam (No. 2721)  
Daniel A. Taylor (No. 6934)  
SMITH, KATZENSTEIN & JENKINS LLP  
1000 West Street, Suite 1501  
Wilmington, DE 19801  
(302) 652-8400  
nbelgam@skjlaw.com  
dtaylor@skjlaw.com

*Attorneys for Defendants Zenara Pharma  
Private Limited and Biophore Indian  
Pharmaceuticals Private Ltd.*

Dated: August 10, 2023

SO ORDERED, this 16th day of August, 2023.

/s/ Richard G. Andrews

United States District Judge